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509Abstracts
costs of aggregate back pain were $14,701,417,650,
work-related back pain were $2,643,650,647, and missed
workdays back pain were $5,396,355,220. With regard
to aggregate back pain, higher proportions of direct costs
were incurred for ofﬁce-based medical provider visits at
$5,768,302,826 (mean = $68; 95% C.L. = $61 to $75),
inpatient visits at $4,658,655,867 (mean = $10,016; 
95% C.L. = $9,463 to $10,570), and outpatient visits 
at $2,050,207,343 (mean = $274; 95% C.L. = $204 to
$345). Lower proportions of direct costs were incurred
for prescriptions, home health visits, and emergency room
visits. CONCLUSIONS: Direct costs associated with
back pain are sizable. As direct costs of occupationally
related back pain were substantially lower than total
direct costs of $14.7 billion, Workman’s Compensation
claims may underestimate the true impact of back pain
on medical care utilization and expenditure.
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OBJECTIVES: To estimate the socio-economic burden of
migraine by calculating the direct and indirect costs of the
disease. METHODS: The prevalence approach was used
to calculate the annual direct (pharmacy, specialist and
primary care consultations, emergency room visits) and
indirect (missed workdays and reduced performance at
work) costs of migraine in Spain in 2001. Data was
extracted from published epidemiological and resource
use studies which used the International Headache
Society diagnostic criteria and from publicly available
ofﬁcial and unofﬁcial databases. The indirect costs were
calculated by the human capital approach using the
model developed by Hu XH et al. RESULTS: The current
Spanish population suffering from migraine was esti-
mated at 3,617,600 patients of whom 92.5% were of an
age to work. The economic burden of migraine was
greater than €1500 million. The direct costs represented
only 21.9% of the total burden (€331 million), of which
40.7% was attributable to primary care ofﬁce visits,
29.8% to specialist consultations, 17.3% to emergency
room visits and a further 12.1% to migraine-speciﬁc 
prescription drugs (triptans 11.2%, ergots 0.9%). The
indirect cost was estimated at €1177 million annually,
which represents a cost per working migraine-sufferer of
€729.46. Most indirect costs (almost €660 million) were
due to migraine-related missed workdays. CONCLU-
SIONS: As in many other developed countries, migraine
puts a considerable economic burden on Spanish society,
especially in terms of work losses. Therefore, activities
should be aimed speciﬁcally at reducing the indirect costs
of the disease, and effective treatments, which have
demonstrated a signiﬁcant reduction in work losses,
should be publicly promoted.
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OBJECTIVES: Epilepsy is one of the most frequent neu-
rological disorders. One-third of epileptic patients suffer-
ing from partial onset seizures cannot be satisfactorily
controlled despite the availability of a large number of
anti-epileptic drugs. The present study reports on an eco-
nomic evaluation of Levetiracetam (LEV) used as an add-
on therapy in refractory epileptic patients. METHODS:
A cost-effectiveness analysis was done using data derived
from three randomised clinical trials. A dose escalation
decision model comparing LEV add-on to standard
therapy alone was designed. Total treatment cost esti-
mates were based on seizure-related costs, routine follow-
up of patients, cost of adverse events as well as LEV
acquisition cost. The perspective is that of the Ontario
(Canada) Ministry of Health. As time horizon for the esti-
mation of costs is one year, no discounting was applied.
Treatment effectiveness was measured by the number 
of seizure free days gained (SFDs). Extensive sensitivity
analyses were performed to test the robustness of the
results, including inclusion of the costs of pre-surgical
evaluation and surgery in addition to the other costs.
RESULTS: Total treatment cost per patient per year was
estimated at Canadian dollars (CAD) 3925 for LEV 
add-on and at CAD 2404 for maintenance of standard
therapy—the difference was mainly related to drug acqui-
sition costs. LEV add-on was associated with an incre-
mental gain of 19 SFDs per patient per year. As such, the
incremental cost effectiveness ratio was CAD 80.7 per
seizure free day gained. When costs associated with pre-
surgical evaluation and surgery were considered, the LEV
add-on approach was in a dominant situation leading to
cost savings of CAD 5871 per patient per year. CON-
CLUSIONS: This economic evaluation demonstrates that
Levetiracetam add-on is a cost-effective alternative to
maintenance of standard therapy for the treatment of
refractory epilepsy.
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OBJECTIVES: Topiramate as add-on treatment is 
effective in patients with refractory epilepsy. Since there
has been less research aimed at evaluating its cost-
